Summary: The European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS) presented in 2025 a targeted update of the management of patients with dyslipidaemia, limited to selected areas, with particular emphasis on updated risk assessment algorithms and new therapeutic options. The clinical and therapeutic goals outlined in the update remain unchanged, with effective reduction of LDL-C levels continuing to be the key priority. The recommendations maintain the indication for the use of high-dose EPA in combination with statin therapy in patients at high or very high cardiovascular risk with elevated triglyceride levels, in order to reduce the risk of cardiovascular events (class IIa recommendation). The 2025 ESC/EAS guidelines also uphold the position that statins constitute first-line therapy in the treatment of hypertriglyceridaemia (excluding severe hypertriglyceridaemia), with EPA as second- -line therapy and fibrates as a subsequent add-on option. In the 2025 ESC/EAS guideline update, anew therapeutic option – volanesorsen – has been introduced with a high class of recommendation (IIa). According to the recommendations, its use should be considered in patients with severe hypertriglyceridaemia caused by familial chylomicronaemia syndrome. However, the updated guidelines do not take into account the results of important clinical trials, such as the ACCORDION study. The aim of this article is to evaluate the ESC/EAS recommendations in the context of current scientific evidence, clinical experience, and the position of Polish experts expressed in the Fifth Sopot Declaration – a document of significant practical value that takes into account the realities of clinical practice in Poland and the implications for real-world therapeutic management of Polish patients.